J&J
This article was originally published in The Tan Sheet
Executive Summary
McNeil consumer franchise generated "modest" 2% sales growth - primarily in the U.S. -during Q3, although prescription COX-2 inhibitors continue to negatively affect Tylenol sales, firm says in Oct. 16 analysts call. Reintroduction of St. Joseph aspirin for adult cardiotherapy, acquisition of Viactiv calcium chews from Mead Johnson were "positive contributors" to growth. J&J worldwide consumer sales rose 3.2% to $1.78 bil., including negative currency impact, with skin care sales up 10% operationally. Consolidated sales jumped 10.8% to $8.24 bil., with net earnings of $1.53 bil., a 15.6% swell
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning